Last edition
News about " Halda Therapeutics"
Johnson & Johnson Acquires Halda Therapeutics to Strengthen Oncology Pipeline with RIPTAC Platform
Johnson & Johnson has completed the acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company developing oral, targeted therapies for solid tumours using its proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC) platform. The transaction was completed for USD 3.05 billion in cash.
Halda Therapeutics | 31/12/2025 | By Darshana | 215
Johnson & Johnson to Acquire Halda Therapeutics for USD 3.05 Billion
Johnson & Johnson has struck a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotech company, for USD 3.05 billion in cash. Halda is known for its proprietary RIPTAC™ platform, which enables the development of oral, precision cancer therapies.
Halda Therapeutics | 18/11/2025 | By Darshana | 158
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy